Efficacy, safety and response predictors of adjuvant astragalus for diabetic kidney disease (READY): study protocol of an add-on, assessor-blind, parallel, pragmatic randomised controlled trial

Abstract

IntroductionDiabetic kidney disease (DKD) is a prevalent and costly complication of diabetes with limited therapeutic options, being the leading cause of end-stage kidney disease in most developed regions. Recent big data studies showed that add-on Chinese medicine (CM) led to a reduced risk of end-stage kidney disease and mortality among patients with chronic kidney disease (CKD) and diabetes. Astragalus, commonly known as huang-qi, is the most prescribed CM or used dietary herb in China for diabetes and DKD. In vivo and in vitro studies showed that astragalus ameliorated podocyte apoptosis, foot process effacement, mesangial expansion, glomerulosclerosis and interstitial fibrosis. Nevertheless, the clinical effect of astragalus remains uncharacterised. This pragmatic clinical trial aims to evaluate the effectiveness of add-on astragalus in patients with type 2 diabetes, stage 2–3 CKD and macroalbuminuria, and to identify related response predictors.Methods and analysisThis is an add-on, assessor-blind, parallel, pragmatic randomised controlled clinical trial. 118 patients diagnosed with DKD will be recruited and randomised 1:1 to receive 48 weeks of add-on astragalus or standard medical care. Primary endpoints are the changes in estimated glomerular filtration rate and urine albumin-to-creatinine ratio between baseline and treatment endpoint. Secondary endpoints include adverse events, fasting blood glucose, glycated haemoglobin, lipids and other biomarkers. Adverse events are monitored through self-complete questionnaire and clinical visits. Outcomes will be analysed by regression models. Subgroup and sensitivity analyses will be conducted for different epidemiological subgroups and statistical analyses. Enrolment started in July 2018.Ethics and disseminationThis study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West/East/Kowloon Central clusters (UW 16-553/HKEC-2019-026/REC (KC/KE)-19-0049/ER-4). We will report the findings in medical journals and conferences. The dataset will be available on reasonable request.Trial registration numberNCT03535935

Efficacy of Herbal Medicines Intervention for Colorectal Cancer Patients With Chemotherapy-Induced Gastrointestinal Toxicity — a Systematic Review and Meta-Analysis

“…Potential adverse effects of the combination of HMs with chemotherapy may appear due to direct toxic effects of HMs, herb-herb, or herb-drug interactions, which are considered major concerns among patients with CRC, especially for those undergoing active chemotherapy (56). However, commonly used HMs such as C. reticulata, A. membranaceus and SJZD are generally perceived as relatively safe treatments with rarely reported adverse effects (57)(58)(59)(60). Studies on animal and clinical trials have shown the safety of these HMs.…”

Recent Advances in Traditional Chinese Medicine for Treatment of Podocyte Injury

“…More than 60 active ingredients are contained in AS, including AS I-IV, polysaccharides, amino acids and trace elements (Amiri et al, 2020). Chan et al showed that AS reduces macroalbuminuria in patients with type 2 diabetes, stage 2-3 CKD (Chan et al, 2021). Through this RCT, they successfully evaluated the effects of AS and identified related response predictors for more personalized applications and further researches.…”

Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis

“…Previous registry studies showed that individualized Chinese medicine (CM) treatment was associated with slower decline of kidney function and reduced risk of end-stage kidney failure and mortality among patients with CKD and diabetes ( Hsieh et al, 2014 ; Lin et al, 2015 ; Huang et al, 2018 ; Chan et al, 2022 ). CM formulations are prescribed based on symptom-based diagnosis ( Chan et al, 2020a ; Chan et al, 2020b ; Chan et al, 2021a ; Chan et al, 2021b ; Chan et al, 2021c ; Shu et al, 2021 ), which predicts renal function decline independent of blood pressure, blood glucose, lipids, and urine albumin control ( Chan et al, 2021b ). The CM used in these cohorts mostly contained a classical CM formulation, namely, Rehmannia-6 complex (R-6, Liu-wei-di-huang-wan) with variations according to the symptom-based diagnosis.…”